Real-World Registry Study on Clinical Analgesic Effect of Acetylaconitine Tablets

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05687929

Enrollment

3500

Registered

2023-01-18

Start date

2023-03-27

Completion date

2024-12-15

Last updated

2024-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pain

Brief summary

1. To observe the clinical analgesic effect, safety and adverse reactions of acetylaconitine. 2. To study and analyze the main influencing factors of the acetylaconitine tablets.

Detailed description

The outpatients/inpatients meeting the criteria are included into this study after signing the Informed Consent Form. The patients received 5 visits in total, which take place after the patients are included into the real-world study, on the 3rd day after enrollment and at the 1st, 4th, 8th and 12th weeks thereafter, in the form of outpatient follow-up, telephone follow-up and APP follow-up.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients with chronic pain \> 1 month and VAS \> 40 mm Patients who can take the acetylaconitine tablets orally

Exclusion criteria

* Patients who cannot communicate or receive follow-up Patients allergic to acetylaconitine Patients who have taken the acetylaconitine drugs orally

Design outcomes

Primary

Measure	Time frame	Description
VAS (0-100mm), IDpain	December 2022 to December 2023	Pain score

Countries

China

Contacts

Primary ContactMa Ke, doctor

marke72@163.com13361879260

Outcome results